Xilio Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
10. Net Loss Per Share
The Company calculates basic net loss per share by dividing net loss by the weighted average number of shares of common stock outstanding. The weighted average number of shares of common stock used in the basic and diluted net loss per share calculation includes the prefunded warrants to purchase common stock issued in connection with the Company’s private placements with certain existing investors and Gilead and the Company’s follow-on public offering, as the prefunded warrants are exercisable at any time for nominal cash consideration. As of September 30, 2025, no prefunded warrants have been exercised and 92,278,707 prefunded warrants are outstanding.
The following table sets forth the outstanding shares of common stock equivalents, presented based on amounts outstanding at each period end, that were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have been anti-dilutive:
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2025 | 2024 | |
| Unvested restricted stock units | 334,125 | 445,500 |
| Outstanding stock options | 11,513,192 | 8,006,371 |
| Common stock warrants | 200,030,631 | 2,631 |
| Unvested employee stock purchase plan shares | 62,339 | 37,097 |
| Total common stock equivalents | 211,940,287 | 8,491,599 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.